Regor Therapeutics

Regor Therapeutics is a clinical-stage company focused on discovering and developing innovative medicines for a range of therapeutic areas, including oncology, immunology, and metabolic disorders. Their proprietary CARD (Computer Accelerated Rational Discovery) platform enables them to efficiently identify and develop novel drug candidates. Regor Therapeutics is developing targeted therapies for various cancer types, immune-mediated disease, and metabolic disorders. Their two lead products are RGT-075, a highly selective oral GLP-1 agonist being developed for the treatment of obesity and related metabolic disorders, and RGT-419B, a CDK4 inhibitor being investigated for the treatment of breast cancer.

Jobs: